Clinical Trials Logo

Filter by:
NCT ID: NCT02996526 Completed - Vocal Cord Paresis Clinical Trials

The Incidence and Impact of Vocal Cord Dysfunction In Patients Undergoing Thoracic Surgery

Start date: September 1, 2016
Phase:
Study type: Observational [Patient Registry]

Population-based single centre, blinded, prospective cohort study of the impact of recurrent laryngeal nerve (RLN) injury on Thoracic Surgery patients. The principal outcome of interest is the effect of RLN injury on respiratory complications. Voice, swallowing, cardiac and mortality outcomes will also be determined.

NCT ID: NCT02996110 Completed - Advanced Cancer Clinical Trials

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

FRACTION-RCC
Start date: February 2, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

NCT ID: NCT02995291 Completed - Anesthesia, Local Clinical Trials

Reversing the Effects of 0.5% Bupivacaine

Start date: February 10, 2017
Phase: Phase 4
Study type: Interventional

Clinical trials have shown phentolamine mesylate (PM), brand name OraVerse, to be effective at reducing the amount of time to reversal of local anesthesia with different dental anesthetics. However, to date no study investigated the efficacy of phentolamine mesylate to reverse anesthesia induced with the use of Bupivacaine. The objective of the proposed research is to conduct a pilot-scale randomized clinical trial evaluating the difference in time required for the return of normal soft-tissue sensation and function in participants who have received 0.5% Bupivacaine HCl, 1:200,000 epinephrine, followed by an injection with either 1) OraVerse (phentolamine mesylate) or 2) sterile physiological water (control).

NCT ID: NCT02995265 Completed - Conditions Clinical Trials

Exoskeleton for Post-Stroke Recovery of Ambulation

ExStRA
Start date: May 1, 2017
Phase: N/A
Study type: Interventional

To determine the effect of using a robotic exoskeleton to allow walking practice after stroke, compared to usual physiotherapy care, on recovery of walking ability and secondary outcomes.

NCT ID: NCT02995057 Completed - Clinical trials for Allergic Reaction to Nickel

Safety Demonstration of Microneedle Insertion

Start date: August 2015
Phase: N/A
Study type: Observational

Hypodermic needles are conventionally used to deliver drugs and vaccines into the muscle of humans and animals. Side effects of these needle injections are pain, bleeding, and anxiety in patients. An alternative drug and vaccine delivery method is the use of hollow microneedles, which are sub-millimeter needle-like structures. Microneedles are pain- and bleeding-free, as they do not reach the nerve-endings and blood capillaries in the skin. As a result, they are better received by patients and do not induce needle anxiety. As the investigators' microneedles are made of gold- or silver-coated, as well as uncoated nickel, the purpose of this study is to observe their biocompatibility and inertness.

NCT ID: NCT02994966 Completed - Diabetic Foot Ulcer Clinical Trials

Diabetes Foot Care Clinical Pathway - Orpyx Medical Technologies

DFCCP-Orpyx
Start date: November 2016
Phase: N/A
Study type: Interventional

In 2011, the premiers of all Canadian provinces and territories selected diabetes foot care as one of three significant targets for pan-provincial action. The Diabetes Foot Care Clinical Pathway Project (DFCCPP) aims to optimize methods of early detection and treatment of foot ulcers in an effort to reduce lower limb amputation (LLA) by 50%. The DFCCPP key deliverables apply consistency in assessment, care, treatment and process standards, early intervention and complex wound care management, while optimizing health outcomes. To achieve these deliverables, High Risk Foot Teams (HRFTs) will be implemented across the province starting with three pilot sites (Slave Lake, Brooks, and outpatient clinics at the Peter Lougheed Hospital). The pilot site facilities were selected on the basis of their employing staff with expertise and knowledge in diabetic foot care. The HRFT will assess and treat patients with moderate and high-risk findings, and this care pathway will then be rolled out to all clinicians who perform diabetic foot assessments (Primary Care, Home Care, Diabetes Centers, First Nations Reserves, etc.). In conjunction with the DFCCPP, we will evaluate the efficacy of a technological device developed by Alberta-based small-medium enterprise (SME) to improve diabetic foot outcomes by preventing future wounds in high-risk patients who have recently been treated for active foot ulcers. This technology is the SurroSense Rx® smart insole system (Orpyx Medical Technologies Inc., Calgary AB), a device that provides dynamic offloading guidance to patients, in addition to enabling ongoing adherence tracking by the HRFT. It is hypothesized that early wound detection and treatment will ultimately lead to improvements in wound prevalence, chronic wound care, and reduce the need for surgical intervention, including LLA.

NCT ID: NCT02994927 Completed - Clinical trials for ANCA-Associated Vasculitis

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

ADVOCATE
Start date: March 15, 2017
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.

NCT ID: NCT02994615 Completed - Clinical trials for Hypertrophic Cardiomyopathy

Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy

PRIMARy
Start date: January 2017
Phase:
Study type: Observational

Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.

NCT ID: NCT02994446 Completed - Clinical trials for Tachycardia, Ventricular

Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia

SERF-VT
Start date: December 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the technical feasibility of the SERF Catheter and SERF Cardiac Ablation System to eliminate or control ventricular tachycardia (VT)

NCT ID: NCT02993822 Completed - Clinical trials for Chronic Refractory Cough

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Start date: May 22, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.